A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and hedge fund hybrid based in the Western United States. The firm is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices throughout Europe currently has €180M AUM and has raised 6 funds to date with the most recent fund vintage in 2011. The firm typically allocates up to €10M in equity per company.  The firm’s investment focus is on fast growing high-tech companies in global technology markets such as telecommunications and IT, internet/media, nanotechnology, new materials, electronics, cleantech and life science. The firm invests in companies that are based in Europe. The firm is actively seeking new investments.

In the Life Sciences, the firm seeks to invest in early-stage therapeutic discovery/technology platform, R&D services, and medical device companies. For medical devices, the firm prefers products that are close to market commercialization. The firm is opportunistic in terms of subsectors and indications.  Historically, the firm invested in proteomics, CRO, cell-based expression systems, small molecule drug discovery, cell modeling/viral vector platforms, cancer diagnostics, and drug delivery. The firm does not invest in drug development.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate Venture Capital Arm of a French Medical Gas company is currently seeking to make new investments in the life science space. The firm is open to leading or co-investing with other investors and typical allocations are made in equity ranging from €1-10 million. The firm is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

The firm focuses on medical devices and health IT products that present novel treatment, monitoring, or self-care strategies in either hospital or home settings. In general, the firm is interested in chronic diseases, particularly in COPD, sleep apnea, renal diseases, and Parkinson’s disease. The technology should complement its current portfolio and fit the firms long-term goals. The firm specializes in early stage projects from concept to clinical development.

The firm is looking for competent management teams with some previous experience in taking a company to an exit and understanding of the negotiations throughout the process. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and private equity firm based in California makes equity allocations in advanced biotechnologies such as synthetic biology. The firm is currently seeking opportunities globally.

The firm manages a fund that identifies compelling investment strategies in/around advanced biotechnologies. The fund focuses on scalable, portable and sustainable technologies within high human-imperative sectors such as agriculture-food, energy-resources, industrial chemicals-materials, water-environment, and defense-space. Medical and healthcare-related technology is not of interest at this point. When it comes to development phases, the fund is stage-agnostic and considers from seed and venture stage projects to on-market projects.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early stage venture firm based in New York is investing from its third fund, which closed in 2013. The firm looks to invest in the Healthcare IT sector, and the initial investment size can range from $250k to $10million. The firm typically invests in companies at Seed and Series A stages.

The firm will consider companies across the US, and is currently looking for new opportunities in the Healthcare IT sectors. The firm will not consider devices or biotech companies. In the Healthcare IT sector, the firm is most interested in companies that do not need FDA approvals and focus on data, analytics, Internet, vertical applications and solutions. Historically, the firm was active in companies developing analytical platform, bioinformatics and software used in the pharmaceutical supply chain.

The firm primarily invests in pre-revenue companies, and prefers to invest in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global healthcare investment firm, headquartered in New York, is investing from an evergreen Life Sciences investment fund.

Typical allocations are up to $5M in early stage projects and $10-15M in late stage projects. With follow-on allocations, the total investment can reach up to $30M per company. The firm takes a mid- to long-term investment approach. The firm leverages flexible capital structures and can invest in both private and public companies. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities with 80% focus on US and Canada and 20% on Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which help women give birth to healthy children.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com